Mevion Medical Systems
Mevion Medical files for $69M IPO
Mevion Medical registered for a $69 million initial public offering as it gears up to commercialize its proton therapy system.
Cancer: Mevion Medical lands $55M to deploy proton therapy system
Massachusetts-based Mevion Medical secured $55 million in funding in support of accelerated deployment of the company’s single-room-proton therapy systems, a smaller, cheaper radiation therapy system for targeting cancerous tumors.
Mevion reported that it raised the funds from existing equity investors Caxton Heath Life Sciences, ProQuest Investments, Venrock, and CHL Medical Partners, as well as through debt financing provided by Life Sciences Alternative Funding.
Mevion lands FDA 510(k) for proton therapy system | Regulatory Roundup
Medtronic wins Canadian approval for brain-stim therapy for epileptics | Regulatory Roundup
iRobot invests $6M into telemedicine company | Funding Roundup
iRobot Corp. (NSDQ: IRBT), famous for their Roomba automated cleaning robots, invested $6 million and launched an extended partnership with InTouch Health, which develops telemedicine systems for providing remote health care.
The venture builds on an existing relationship that the companies announced last summer, under which the companies engaged in a development and licensing agreement.
Still River Systems rebrands as Mevion Medical, gears up for proton therapy commercialization
Still River Systems Inc. change its name to Mevion Medical Systems Inc. ahead of its push to get its proton therapy device, the Mevion S250, to market.
The Littleton, Mass.-based firm’s move marks its shift from a research & development company to a commercial manufacturer, according to a press release.
Proton therapy delivers therapeutic doses of radiation to tumors. Because the systems are so large and expensive it’s not widely available, a situation Mevion aims to change.
